指南与共识消化道肿瘤与早癌消化内镜

AGA临床实践指南:Barrett食管及相关肿瘤的内镜下根除治疗

AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett's Esophagus and Related Neoplasia.
指南 / 共识 · Gastroenterology · 2024-01-01

本指南由AGA采用GRADE框架制定,针对Barrett食管(BE)及相关肿瘤的内镜下根除治疗(EET)给出5条推荐。对BE伴高级别上皮内瘤变强推荐EET,对无上皮内瘤变者条件推荐反对EET,对低级别上皮内瘤变条件推荐支持EET;可见病灶者条件推荐局灶EMR联合消融优于分步EMR;切除可见肿瘤性病灶时,根据病灶特征建议选择EMR或ESD。

要点

  • BE伴高级别上皮内瘤变:强推荐EET。
  • BE不伴上皮内瘤变:条件推荐反对EET。
  • BE伴低级别上皮内瘤变:条件推荐支持EET,重视潜在危害者可选择监测内镜。

核心结论

  • 本文件全面概述了EET在BE及相关肿瘤管理中的适应证,并提供了EET实施的考虑因素。
  • 提供者应基于患者偏好进行共享决策。
  • 原文指出证据的局限与空白以指导未来研究方向。

研究设计与样本

  • 采用推荐分级的评估、制定与评价(GRADE)框架评估证据并制定推荐。
  • 专家组根据对临床医生和患者的重要性优先确定临床问题与结局,进行证据回顾,并使用证据至决策框架制定推荐。
  • 推荐基于 desirable 与 undesirable 效应、患者价值观、成本和健康公平考虑之间的平衡。

主要发现

  • 专家组就BE及相关肿瘤中EET的使用达成5条推荐。
  • 基于现有证据,对BE伴高级别上皮内瘤变患者强推荐支持EET。
  • 对BE不伴上皮内瘤变患者条件推荐反对EET。
  • 对BE伴低级别上皮内瘤变患者条件推荐支持EET;对潜在危害赋予更高价值、对降低食管癌死亡率的获益(不确定)赋予更低价值的BE低级别上皮内瘤变患者,可合理选择监测内镜。
  • 对可见病灶患者,条件推荐局灶EMR联合消融优于分步EMR。

关键数值与推荐

  • BE伴高级别上皮内瘤变:强推荐支持EET。
  • BE不伴上皮内瘤变:条件推荐反对EET。
  • BE伴低级别上皮内瘤变:条件推荐支持EET;重视潜在危害且对降低食管癌死亡率获益(不确定)重视较低的患者可合理选择监测内镜。
  • 可见病灶:条件推荐局灶EMR联合消融优于分步EMR。
  • 可见肿瘤性病灶接受切除:根据病灶特征建议选择EMR或ESD。

临床怎么用

  • 原文未据此给出具体的临床实施推荐,仅指出提供者应基于患者偏好进行共享决策。

局限性

  • 原文指出证据存在局限与空白,以指导未来研究方向。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Barrett's esophagus (BE) is the precursor to esophageal adenocarcinoma (EAC). Endoscopic eradication therapy (EET) can be effective in eradicating BE and related neoplasia and has greater risk of harms and resource use than surveillance endoscopy. This clinical practice guideline aims to inform clinicians and patients by providing evidence-based practice recommendations for the use of EET in BE and related neoplasia. METHODS: The Grading of Recommendations Assessment, Development and Evaluation framework was used to assess evidence and make recommendations. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients, conducted an evidence review, and used the Evidence-to-Decision Framework to develop recommendations regarding the use of EET in patients with BE under the following scenarios: presence of (1) high-grade dysplasia, (2) low-grade dysplasia, (3) no dysplasia, and (4) choice of stepwise endoscopic mucosal resection (EMR) or focal EMR plus ablation, and (5) endoscopic submucosal dissection vs EMR. Clinical recommendations were based on the balance between desirable and undesirable effects, patient values, costs, and health equity considerations. RESULTS: The panel agreed on 5 recommendations for the use of EET in BE and related neoplasia. Based on the available evidence, the panel made a strong recommendation in favor of EET in patients with BE high-grade dysplasia and conditional recommendation against EET in BE without dysplasia. The panel made a conditional recommendation in favor of EET in BE low-grade dysplasia; patients with BE low-grade dysplasia who place a higher value on the potential harms and lower value on the benefits (which are uncertain) regarding reduction of esophageal cancer mortality could reasonably select surveillance endoscopy. In patients with visible lesions, a conditional recommendation was made in favor of focal EMR plus ablation over stepwise EMR. In patients with visible neoplastic lesions undergoing resection, the use of either endoscopic mucosal resection or endoscopic submucosal dissection was suggested based on lesion characteristics. CONCLUSIONS: This document provides a comprehensive outline of the indications for EET in the management of BE and related neoplasia. Guidance is also provided regarding the considerations surrounding implementation of EET. Providers should engage in shared decision making based on patient preferences. Limitations and gaps in the evidence are highlighted to guide future research opportunities.

来源:Gastroenterology,查看原文。版权归原作者所有。

引用

  1. Rubenstein JH, Sawas T, Wani S, et al. AGA Clinical Practice Guideline on Endoscopic Eradication Therapy of Barrett's Esophagus and Related Neoplasia. Gastroenterology. 2024. PMID: 38763697. doi:10.1053/j.gastro.2024.03.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。